{"id":"https://openalex.org/W2072008776","doi":"https://doi.org/10.1007/s00213-015-3920-3","title":"Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia","display_name":"Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia","publication_year":2015,"publication_date":"2015-04-13","ids":{"openalex":"https://openalex.org/W2072008776","doi":"https://doi.org/10.1007/s00213-015-3920-3","mag":"2072008776","pmid":"https://pubmed.ncbi.nlm.nih.gov/25869273"},"language":"en","primary_location":{"id":"doi:10.1007/s00213-015-3920-3","doi":"https://doi.org/10.1007/s00213-015-3920-3","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00213-015-3920-3","pdf_url":null,"source":{"id":"https://openalex.org/S80334769","display_name":"Psychopharmacology","issn_l":"0033-3158","issn":["0033-3158","1432-2072"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Psychopharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039021133","display_name":"Shigeyuki Chaki","orcid":"https://orcid.org/0000-0003-4444-2911","observed_orcids":["https://orcid.org/0000-0003-4444-2911","https://orcid.org/0000-0001-5608-4192"]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Shigeyuki Chaki","raw_affiliation_strings":["Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan, s-chaki@so.taisho.co.jp","Pharmacology Laboratories Taisho Pharmaceutical Co., Ltd. Saitama Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan, s-chaki@so.taisho.co.jp","institution_ids":["https://openalex.org/I144245601"]},{"raw_affiliation_string":"Pharmacology Laboratories Taisho Pharmaceutical Co., Ltd. Saitama Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111583362","display_name":"Toshiharu Shimazaki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Toshiharu Shimazaki","raw_affiliation_strings":["Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","Pharmacology Laboratories Taisho Pharmaceutical Co., Ltd. Saitama Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","institution_ids":["https://openalex.org/I144245601"]},{"raw_affiliation_string":"Pharmacology Laboratories Taisho Pharmaceutical Co., Ltd. Saitama Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110093370","display_name":"Jun-ichi Karasawa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Jun-ichi Karasawa","raw_affiliation_strings":["Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","Pharmacology Laboratories Taisho Pharmaceutical Co., Ltd. Saitama Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","institution_ids":["https://openalex.org/I144245601"]},{"raw_affiliation_string":"Pharmacology Laboratories Taisho Pharmaceutical Co., Ltd. Saitama Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108476616","display_name":"Takeshi Aoki","orcid":"https://orcid.org/0009-0006-0623-8484","observed_orcids":["https://orcid.org/0009-0006-0623-8484","https://orcid.org/0000-0001-9194-2623"]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takeshi Aoki","raw_affiliation_strings":["Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","Pharmacology Laboratories Taisho Pharmaceutical Co., Ltd. Saitama Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","institution_ids":["https://openalex.org/I144245601"]},{"raw_affiliation_string":"Pharmacology Laboratories Taisho Pharmaceutical Co., Ltd. Saitama Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011856990","display_name":"Ayaka Kaku","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Ayaka Kaku","raw_affiliation_strings":["Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","Pharmacology Laboratories Taisho Pharmaceutical Co., Ltd. Saitama Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","institution_ids":["https://openalex.org/I144245601"]},{"raw_affiliation_string":"Pharmacology Laboratories Taisho Pharmaceutical Co., Ltd. Saitama Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063039861","display_name":"Michihiko Iijima","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Michihiko Iijima","raw_affiliation_strings":["Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","Pharmacology Laboratories Taisho Pharmaceutical Co., Ltd. Saitama Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","institution_ids":["https://openalex.org/I144245601"]},{"raw_affiliation_string":"Pharmacology Laboratories Taisho Pharmaceutical Co., Ltd. Saitama Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055973215","display_name":"Daiji Kambe","orcid":"https://orcid.org/0000-0001-5134-3554","observed_orcids":["https://orcid.org/0000-0001-5134-3554"]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Daiji Kambe","raw_affiliation_strings":["Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","Pharmacology Laboratories Taisho Pharmaceutical Co., Ltd. Saitama Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","institution_ids":["https://openalex.org/I144245601"]},{"raw_affiliation_string":"Pharmacology Laboratories Taisho Pharmaceutical Co., Ltd. Saitama Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Shuji Yamamoto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shuji Yamamoto","raw_affiliation_strings":["Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","institution_ids":["https://openalex.org/I144245601"]},{"raw_affiliation_string":"Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059509332","display_name":"Yasunori Kawakita","orcid":"https://orcid.org/0009-0002-9830-6173","observed_orcids":["https://orcid.org/0009-0002-9830-6173"]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yasunori Kawakita","raw_affiliation_strings":["Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd, Saitama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","institution_ids":["https://openalex.org/I144245601"]},{"raw_affiliation_string":"Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd, Saitama, Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Tsuyoshi Shibata","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tsuyoshi Shibata","raw_affiliation_strings":["Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","institution_ids":["https://openalex.org/I144245601"]},{"raw_affiliation_string":"Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102075999","display_name":"Kumi Abe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kumi Abe","raw_affiliation_strings":["Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","institution_ids":["https://openalex.org/I144245601"]},{"raw_affiliation_string":"Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090920304","display_name":"Taketoshi Okubo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Taketoshi Okubo","raw_affiliation_strings":["Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","institution_ids":["https://openalex.org/I144245601"]},{"raw_affiliation_string":"Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107840719","display_name":"Yoshinori Sekiguchi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yoshinori Sekiguchi","raw_affiliation_strings":["Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","institution_ids":["https://openalex.org/I144245601"]},{"raw_affiliation_string":"Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110113221","display_name":"Shigeru Okuyama","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shigeru Okuyama","raw_affiliation_strings":["Research Headquarters, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","Research Headquarters, Taisho Pharmaceutical Co., Ltd.Saitama Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Headquarters, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan","institution_ids":["https://openalex.org/I144245601"]},{"raw_affiliation_string":"Research Headquarters, Taisho Pharmaceutical Co., Ltd.Saitama Japan","institution_ids":["https://openalex.org/I144245601"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5039021133"],"corresponding_institution_ids":["https://openalex.org/I144245601"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":null,"fwci":1.4808,"has_fulltext":false,"cited_by_count":27,"citation_normalized_percentile":{"value":0.78815433,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"232","issue":"15","first_page":"2849","last_page":"2861"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12770","display_name":"Amino Acid Enzymes and Metabolism","score":0.011699999682605267,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.003800000064074993,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glycine-transporter-1-inhibitor","display_name":"glycine transporter 1 inhibitor","score":0.8840000033378601},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.8259999752044678},{"id":"https://openalex.org/keywords/negative-symptoms","display_name":"negative symptoms","score":0.7070000171661377},{"id":"https://openalex.org/keywords/cognitive-impairment","display_name":"cognitive impairment","score":0.9810000061988831},{"id":"https://openalex.org/keywords/nmda-receptor-hypofunction","display_name":"NMDA receptor hypofunction","score":0.9279999732971191},{"id":"https://openalex.org/keywords/mk-801","display_name":"MK-801","score":0.8289999961853027},{"id":"https://openalex.org/keywords/phencyclidine","display_name":"phencyclidine","score":0.9010000228881836},{"id":"https://openalex.org/keywords/object-recognition-memory","display_name":"object recognition memory","score":0.7070000171661377},{"id":"https://openalex.org/keywords/social-recognition-memory","display_name":"social recognition memory","score":0.824999988079071},{"id":"https://openalex.org/keywords/social-memory","display_name":"social memory","score":0.7419999837875366},{"id":"https://openalex.org/keywords/social-interaction","display_name":"social interaction","score":0.765999972820282},{"id":"https://openalex.org/keywords/antidepressant-effects","display_name":"antidepressant effects","score":0.9359999895095825},{"id":"https://openalex.org/keywords/forced-swim-test","display_name":"forced swim test","score":0.6639999747276306},{"id":"https://openalex.org/keywords/locomotor-activity","display_name":"locomotor activity","score":0.6269999742507935},{"id":"https://openalex.org/keywords/catalepsy","display_name":"catalepsy","score":0.6930000185966492}],"concepts":[{"id":"https://openalex.org/C67018056","wikidata":"https://www.wikidata.org/wiki/Q414896","display_name":"NMDA receptor","level":3,"score":0.7594953775405884},{"id":"https://openalex.org/C2778851735","wikidata":"https://www.wikidata.org/wiki/Q407324","display_name":"Phencyclidine","level":4,"score":0.7478077411651611},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.6113094687461853},{"id":"https://openalex.org/C2780476085","wikidata":"https://www.wikidata.org/wiki/Q918193","display_name":"Catalepsy","level":4,"score":0.5780397653579712},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.5559687614440918},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5086961388587952},{"id":"https://openalex.org/C136569192","wikidata":"https://www.wikidata.org/wiki/Q4880745","display_name":"Behavioural despair test","level":4,"score":0.43318280577659607},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.4260942041873932},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.36011558771133423},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2873430848121643},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.28074347972869873},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.27970877289772034},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.25315752625465393},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.22980618476867676},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.21856805682182312},{"id":"https://openalex.org/C2781161787","wikidata":"https://www.wikidata.org/wiki/Q48360","display_name":"Hippocampus","level":2,"score":0.08390778303146362},{"id":"https://openalex.org/C2780948584","wikidata":"https://www.wikidata.org/wiki/Q251347","display_name":"Haloperidol","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003071","descriptor_name":"Cognition","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D003072","descriptor_name":"Cognition Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003072","descriptor_name":"Cognition Disorders","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004195","descriptor_name":"Disease Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005998","descriptor_name":"Glycine","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008568","descriptor_name":"Memory","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D010622","descriptor_name":"Phencyclidine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D012919","descriptor_name":"Social Behavior","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D016194","descriptor_name":"Receptors, N-Methyl-D-Aspartate","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D050487","descriptor_name":"Glycine Plasma Membrane Transport Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/s00213-015-3920-3","doi":"https://doi.org/10.1007/s00213-015-3920-3","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00213-015-3920-3","pdf_url":null,"source":{"id":"https://openalex.org/S80334769","display_name":"Psychopharmacology","issn_l":"0033-3158","issn":["0033-3158","1432-2072"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Psychopharmacology","raw_type":"journal-article"},{"id":"pmid:25869273","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25869273","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Psychopharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":37,"referenced_works":["https://openalex.org/W1919779618","https://openalex.org/W1964763649","https://openalex.org/W1975682905","https://openalex.org/W1981659136","https://openalex.org/W1981785487","https://openalex.org/W1982722868","https://openalex.org/W1982846983","https://openalex.org/W1983235123","https://openalex.org/W1983805722","https://openalex.org/W1990440194","https://openalex.org/W2002247469","https://openalex.org/W2006644482","https://openalex.org/W2010469749","https://openalex.org/W2011182878","https://openalex.org/W2016729909","https://openalex.org/W2018114814","https://openalex.org/W2020140782","https://openalex.org/W2028884770","https://openalex.org/W2034006349","https://openalex.org/W2043697771","https://openalex.org/W2046411639","https://openalex.org/W2046706409","https://openalex.org/W2049428499","https://openalex.org/W2072990488","https://openalex.org/W2079524104","https://openalex.org/W2085157288","https://openalex.org/W2102874112","https://openalex.org/W2103069362","https://openalex.org/W2110652090","https://openalex.org/W2110678771","https://openalex.org/W2120641846","https://openalex.org/W2145015856","https://openalex.org/W2148049102","https://openalex.org/W2148914011","https://openalex.org/W2150174494","https://openalex.org/W2327693359","https://openalex.org/W2395340796"],"related_works":["https://openalex.org/W1983235123","https://openalex.org/W161171957","https://openalex.org/W2021665131","https://openalex.org/W1966187441","https://openalex.org/W118066032","https://openalex.org/W1013516912","https://openalex.org/W4297984597","https://openalex.org/W2145204418","https://openalex.org/W1516718806","https://openalex.org/W2135205867"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}